(EMA), ATMPs fall into three main categories: somatic cell therapy medicinal products (sCTMPs), gene therapy medicinal products (GTMPs), and tissue-engineered products (TEPs). Each category carries distinct regulatory pathways and standards. In the United States, the FDA classifies ATMPs under its biologics regulations, which include Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) as either 361 HCT/Ps or 351 products. Understanding the nuances of these classifications is vital.

ATMP classification not only dictates the regulatory requirements but also influences the pathway for clinical trials and market authorization. Regulatory professionals must familiarize themselves with the specific definitions and criteria for classification, as outlined in the following key documents:

• EMA’s Classification Guidelines
• FDA’s Guidance on HCT/Ps
• ICH Guidelines

Regulatory professionals should conduct a comprehensive analysis of their product against these criteria and document the arguments for the desired classification. This foundational understanding will assist in addressing subsequent levels of complexity when moving toward product development.

Step 2: Conducting Initial Feasibility Analysis

Once the classification type is established, the next step involves conducting an initial feasibility analysis. This involves a thorough examination of product characteristics, processing methods, and intended use. This analysis should support the initial classification determination and highlight any aspects that may lead to a borderline product classification.

There are several practical actions during this phase:

• Documentation Review: Compile and review existing product data and manufacturing processes. Evaluate how these elements align with regulatory definitions and requirements under both FDA and EMA frameworks.
• Stakeholder Engagement: Engage with key stakeholders, including product developers, scientists, and clinicians, to gather insights on product functionality and potential implications of classification.
• Market Research: Conduct market research and competitive analysis to understand how similar products have been classified and regulated.
• Consult Regulatory Experts: If applicable, consider seeking consulting services specialized in EMA ATMP regulatory consulting to validate findings or fill in gaps in expertise.

The information compiled during this feasibility analysis will serve as a pivotal reference point when preparing for regulatory submissions. Furthermore, it can be valuable in strategic planning for both US and EU market entry.

Step 3: Developing Regulatory Submission Strategy

Following the feasibility analysis, the development of a strategic regulatory submission plan is essential. This strategy should delineate the approach for filing with both the FDA and EMA, taking into account their respective pathways for ATMP classification.

Key components of a regulatory submission strategy include:

• Choosing the Right Pathways: For the EMA, determine whether to pursue classification under the centralised procedure or national procedures based on the intended marketing strategy. For the FDA, decide if the product qualifies as 361 HCT/P or requires full biologics licensing under 351.
• Compile Required Documentation: Each regulatory body requires extensive documentation for submissions. Common documents for both organizations include:
• Quality Data (CMC) – detailing manufacturing processes, quality controls, and stability.
• Pre-Clinical Data – results from required non-clinical studies to ensure product safety and efficacy.
• Clinical Protocols – comprehensive descriptions of designed clinical trials, including endpoints and methodology.
• Interacting with Regulatory Bodies: Schedule pre-submission meetings with both FDA and EMA. These meetings serve as a platform for discussing classification, guidance, and expectations. Prepare a detailed agenda and ensure all relevant stakeholders are involved.

Having a well-structured submission strategy helps minimize the risk of classification issues or regulatory delays, ensuring a smoother path through the regulatory process.

Step 4: Preparing for Clinical Trials

Upon successfully obtaining regulatory classification, attention must be directed toward preparing for clinical trials. Ensuring compliance with Good Clinical Practice (GCP) standards is critical to obtaining valid and reliable trial data.

The following practical steps should be considered:

• Develop a Clinical Trial Protocol: This document outlines the trial objectives, design, methodology, statistical considerations, and organization. It should be detailed enough to ensure reproducibility and compliance.
• Ethics Considerations: Prepare for Institutional Review Board (IRB) or Ethics Committee (EC) submissions, paying special attention to informed consent and patient safety measures.
• Recruitment Strategy: Outline how patients will be recruited, including eligibility criteria and outreach methods. Consider the implications of different regulatory environments in both the US and Europe.
• Regulatory Notifications: Provide all necessary notifications to regulatory bodies regarding trial initiation, including the ClinicalTrials.gov registration for all US trials.

Documentation during this phase must be meticulously maintained and prepared, as it will also serve as a valuable resource for subsequent submission phases and regulatory reviews.

Step 5: Executing the Submission Process

Once clinical trials have generated sufficient data, the next phase is executing the regulatory submission process. Both the FDA and EMA have specific requirements for submission formats and content that must be adhered to strictly.

Key steps in this phase include:

• Preparation of Regulatory Dossiers: Prepare the Common Technical Document (CTD) format as required by both FDA and EMA. Each section of the CTD should be comprehensive and clearly support the claims made regarding the product.
• Addressing Regulatory Feedback: Pay close attention to feedback received during any interaction with regulatory agencies, including pre-submission meetings. All concerns raised must be addressed in the submission.
• Submission Timing: Carefully time the submissions to ensure alignment with your clinical development plan and planned market entry date.
• Tracking Applications: Utilize project management tools to track the progress of submissions with both agencies. Maintain a clear overview of timelines and outstanding actions.

Successful execution in this step includes ensuring all necessary documents are submitted and accurately reflect the findings from both preclinical and clinical phases.

Step 6: Engaging in Regulatory Review and Response

After submission, the regulatory review process commences. During this phase, close monitoring and prompt responses to any queries from the agencies is crucial.

Here are specific actions to consider:

• Engage with Review Teams: Maintain regular communication with the review teams. This may involve follow-up meetings or discussions to clarify submitted documents and data.
• Prepare for Potential Queries: Be prepared for requests for additional data or clarification on specific aspects of the submission. Having a dedicated team to respond to queries can enhance the review process.
• Timely Resubmissions: If any issues arise necessitating a resubmission, act promptly to resolve and submit the required changes. This action is crucial in maintaining a good rapport with regulatory agencies.

Effective engagement during the review phase can significantly influence the speed of approval and eventual market authorization for the ATMP.

Step 7: Post-Approval Commitments and Monitoring

Once an ATMP receives the approval, the focus shifts towards post-approval commitments and market behavior monitoring. Regulatory compliance does not cease with approval; continuous monitoring and reporting are responsibilities that fall within the mandate of the product sponsor.

Activities in this phase should include:

• Post-Marketing Surveillance: Plan and execute post-marketing studies to assess long-term product safety and efficacy. This may include registries or additional clinical trials to gather data on real-world use.
• Adverse Event Reporting: Establish robust systems for monitoring and reporting any adverse events associated with the product once it is on the market. Compliance with regulatory timelines for reporting is essential.
• Periodic Safety Update Reports (PSURs): Prepare and submit PSURs as required by both the FDA and EMA. These reports provide regulators with updated safety information and confirm adherence to commitments made during the approval process.
• Engaging with Regulatory Authorities: Maintain an ongoing relationship with regulatory bodies. Be proactive in sharing data and updates, as well as addressing any feedback that may arise post-approval.

Through diligent post-approval activities, pharmaceutical companies can ensure ongoing compliance and continue safe patient access to ATMPs.

Conclusion

This tutorial has outlined the step-by-step process of navigating the complexities of ATMP classifications and regulatory pathways in a US context for both the FDA and EMA. Through thorough understanding, careful planning, and effective communication, regulatory professionals can ensure that their ATMPs are successfully classified and brought to market while maintaining compliance with relevant regulations.